Table 1. Key characteristics and published references for the pooled dataset of severe-malaria patients.
| Study name | Study countries | Number of patients | In-hospital mortality (%) | Median age, years (range) | Parenteral antimalarial treatments | References |
|---|---|---|---|---|---|---|
| Core Malaria | Thailand Bangladesh |
1,107 | 22 | 26 (1–80) | Artemether Artesunate Quinine |
[22] [21] [24] [20] [23] |
| AAV | Vietnam | 370 | 10 | 32 (15–77) | Artemether Artesunate |
[26] |
| AQ | Vietnam | 560 | 15 | 30 (15–79) | Artemether Quinine |
[27] |
| QC | The Gambia | 48 | 17 | 4.5 (1–10) | Quinine Chloroquine |
[25] |
| SEAQUAMAT | Bangladesh Myanmar India Indonesia |
1,461 | 19 | 25 (2–87) | Artesunate Quinine |
[5] |
| AQUAMAT | Mozambique Ghana Kenya The Gambia Nigeria Tanzania Uganda Rwanda DRC |
5,494 | 10 | 2 (0–78) | Artesunate Quinine |
[28] |
| Overall | - | 9,040 | 13 | 4 (0–87) |
AAV, AQ, QC, SEAQUAMAT, and AQUAMAT were randomised controlled trials.
Abbreviation: AAV, artemether versus artesunate trial in Vietnam; AQ, artemether versus quinine trial in Vietnam; AQUAMAT, Africa multinational quinine versus artesunate in severe-malaria trial; DRC, Democratic Republic of Congo; QC, quinine versus chloroquine trial in The Gambia; SEAQUAMAT, South East Asian multinational quinine versus artesunate malaria trial.